期刊文献+

子宫内膜癌分子标志物与临床病理特征及预后的关系 被引量:11

Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma
暂未订购
导出
摘要 目的:探讨子宫内膜癌中雌激素受体(estrogen receptor,ER)、孕激素受体(progestin receptor,PR)、第10染色体同源缺失性磷酸酶-张力蛋白基因(phosphatase and tension homology deleted on chromosome ten,PTEN)、p53及Ki-67的表达与临床、病理特征及预后的关系。方法:收集200例原发性子宫内膜癌患者的临床信息、组织病理、免疫组织化学结果及随访资料,进行统计学分析。结果:(1)子宫内膜癌病例中ER、PR、PTEN、p53的阳性表达率分别为86.5%、85.5%、82.1%和49.2%;Ki-67在癌灶中的阳性表达率为46.9%±24.7%。(2)妊娠次数与PR阳性表达呈负相关(r=-0.191,P=0.007),而发病年龄、分娩次数与p53阳性表达呈正相关(r=0.184,P=0.041;r=0.255,P=0.004)。(3)子宫内膜样腺癌中ER、PR、p53阳性率与其他类型内膜癌比较差异有统计学意义(P<0.01)。(4)ER阳性表达与手术病理分期呈负相关(r=-0.176,P=0.013),其中Ⅰ期患者的ER阳性率高于Ⅱ期及以上患者(P=0.015)。(5)ER、PR阳性表达与组织学分级呈负相关(r=-0.217,P=0.002;r=-0.317,P=0.000),但p53、Ki-67表达与其呈正相关(r=0.327,P=0.000;r=0.465,P=0.000);组织学Ⅲ级的ER、PR、p53、Ki-67表达与其他级别比较差异有统计学意义(P<0.01)。(6)ER阳性表达与肌层浸润深度呈负相关(r=-0.142,P=0.047),有或无深肌层浸润两者比较,ER、PR表达率差异均有统计学意义(P<0.05)。(7)多因素生存分析显示,PR表达的差异对总生存时间的影响有统计学意义(P=0.011)。结论:术前对诊断性刮宫标本进行免疫组织化学研究有助于全面了解子宫内膜癌的临床病理特征;除PR外,ER、PTEN、p53及Ki-67的表达情况对患者临床预后的预测意义较小。 Objective:To explore the relationships between the expressions of estrogen receptor(ER),progestin receptor(PR),phosphatase and tension homology deleted on chromosome ten(PTEN),p53,Ki-67 and the clinicopathologic features and prognosis in endometrial carcinoma.Methods: The data of clinical characteristics,pathological types,histological grades,follow-ups and the expressions of molecular markers detected by immunohistochemistry,and collected from 200 patients with primary endometrial carcinoma,were analyzed.Results:(1) In the cases of endometrial carcinoma,the expression rates of ER,PR,PTEN,p53 were 86.5%,85.5%,82.1%,and 49.2%,respectively.The expression level of Ki-67 in the tumor tissues was 46.9%±24.7%.(2) A negative correlation was observed between the gravidity and the expression of PR(r=-0.191,P=0.007).On the other hand,age and parturition time were in positive correlation with the expression of p53(r=0.184,P=0.041;r=0.255,P=0.004).(3) The expression rates of ER,PR and p53 in the endometrioid carcinoma exhibited significant differences comparing with other types(P0.01).(4) A negative correlation was found between the expression of ER and the FIGO staging(r=-0.176,P=0.013).The positive rate of ER in the cases with Stage Ⅰ was higher than that in cases with Stage Ⅱ and above(P=0.015).(5) A negative correlation was found between the histological grade and the expressions of ER and PR(r=-0.217,P=0.002;r=-0.317,P=0.000),however,a positive correlation was detected between the grade with the expressions of p53 and Ki-67(r=0.327,P=0.000;r=0.465,P=0.000).Compared with the grade 3 tumors,the other grades exhibited significant different expression levels of ER,PR,p53,and Ki-67(P0.01).(6) A negative correlation was observed between the depth of myometrial invasion and the positive rate of ER(r=-0.142,P=0.047).There were statistically significant different expression rates of ER and PR between the cases whether the cancer invaded the deep myometrium or not(P0.05).(7) Multivariate survival analysis showed that patients with PR(+) had longer overall survival than those with PR(-)(P=0.011).Conclusion: The immunohistochemical study of endometrium samples obtained from dilatation and curettage of uterine will be beneficial to the understanding of the clinicopathologic features of the endometrial carcinoma before the operation.The value of estimating the prognosis using the expressions of ER,PTEN,p53 and Ki-67 was negative,except for the expression of PR.
出处 《北京大学学报(医学版)》 CAS CSCD 北大核心 2011年第5期743-748,共6页 Journal of Peking University:Health Sciences
基金 教育部高等学校博士学科点专项科研基金(20090001110085)资助~~
关键词 子宫内膜肿瘤 受体 雌激素 孕激素类 免疫组织化学 预后 Endometrial neoplasms Receptors estrogen Progestins Immunohistochemistry Prognosis
  • 相关文献

参考文献13

  • 1Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics,2002[J].CA Cancer J Clin,2005,55(2):74-108.
  • 2王建六,魏丽惠,薛凤霞,王志启.晚期子宫内膜癌20例复发转移特征及相关因素分析[J].中国实用妇科与产科杂志,2003,19(9):537-540. 被引量:8
  • 3Idrees MT,Schlosshauer P,Li G,et al.GLUT1 and p63 expression in endometrial intraepithelial and uterine serous papillary carcinoma[J].Histopathology,2006,49(1):75-81.
  • 4Bokhman JV.Two pathogenetic types of endometrial carcinoma[J].Gynecol Oncol,1983,15(1):10-17.
  • 5Jeon YT,Park IA,Kim YB,et al.Steroid receptor expressions in endometrial cancer:clinical significance and epidemiological implication[J].Cancer Lett,2006,239(2):198-204.
  • 6高敏,魏丽惠,孙蓬明,赵丹,李小平.雌激素受体相关受体α和雌激素受体α在子宫内膜癌中的表达及临床意义[J].北京大学学报(医学版),2006,38(5):463-465. 被引量:14
  • 7王志启,王建六,郭健,魏丽惠.内分泌辅助治疗子宫内膜癌的临床意义[J].中华医学杂志,2005,85(34):2414-2419. 被引量:21
  • 8Salvesen HB,Stefansson I,Kalvenes MB,et al.Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma[J].Cancer,2002,94(8):2185-2191.
  • 9Salvesen HB,Stefansson I,Kretzschmar EI,et al.Significance of PTEN alterations in endometrial carcinoma:a population-based study of mutations,promoter methylation and PTEN protein expression[J].Int J Oncol,2004,25(6):1615-1623.
  • 10Erkanli S,Kayaselcuk F,Kuscu E,et al.Expression ofsurvivin,PTEN and p27 in normal,hyperplastic,and carcinomatous endometrium[J].Int J Gynecol Cancer,2006,16 (3):1412-1418.

二级参考文献34

  • 1彭芝兰.子宫内膜癌的治疗[A].见:曹泽毅主编.中华妇产科学[C].北京:人民卫生出版社,2001.1856.
  • 2Aoki Y,Kase H,Watanabe M,et al. Stage Ⅲ endometrial cancer:analysis of prognostic factors and failure patterns after adjuvant chemotherapy. Gynecol Oncol,2001,83 ( 1 ) : 1.
  • 3Trope C, Kristense GB ,Abeler VM. Clear - cell and papillary serous cancer: treatment options. Best Pract Res Clin Obstet Gynecol,2001,15:433.
  • 4Umasaki N, Tanaka T, Miyana M, et al. Postoperation adjuvant chemotherapy with cisplatin, etoposide, and pirarubicin for endometrial carcinoma patients with lymph node metastasis:a pilot study.Oncol Rep,2000,7(5) :1083.
  • 5Mundt AJ, Murphy KT, Rotmensch J, et al. Surgery and postoperation radiation therapy in FIGO stage Ⅲc endometrial carcinoma. Int J Radiat Oncol Biol Phys,2001,50(5) :1154.
  • 6Fujimura H, Kikkawa F, Oguchi H, et al. Adjuvant chemotherapy including cisplatin in endometrial carcinoma. Gynecol Obstet Invest,2000,50(2) :127.
  • 7Miller DS, Blessing JA, Lentz SS, et al. A phase Ⅱ trial of Topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol, 2002,87:247.
  • 8Silverberg S. Protocol for the examination of specimen from patients with carcinomas of endometrium: a basis for checklists. Cancer Committee, College of American Pathologists. Arch Pathol Lab Med,1999,123 ( 1 ) :28.
  • 9Cornio G,Lissoni A,Losa G,et al. Brain metastases from endometrial carcinoma. Gynecol Oncol,1996,61:40.
  • 10Mundt A J, Waggoner S, Yamada D, et al. Age as a prognostic factor for recurrence in patients with endometrial carcinoma. Gynecol Oncol,2000,79:79.

共引文献38

同被引文献116

引证文献11

二级引证文献81

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部